Sugi Predict

Sugi Predict / Compounds / SCHEMBL25316629

SCHEMBL25316629

SCHEMBL25316629

CN(c1c(F)cc(OCCN2CCC3(CC2)C(=O)Nc2ccc(C#N)cc23)cc1F)S(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 6/20 0.40
▸ ALK Q9UM73 5/20 0.39
▸ PTGS2 P35354 1/20 0.37
▸ HTR1A P08908 2/20 0.36
▸ HTR2A P28223 2/20 0.36
▸ HTR7 P34969 2/20 0.36
▸ HTR6 P50406 2/20 0.36
▸ KCNA5 P22460 3/20 0.35
▸ TRPV4 Q9HBA0 1/20 0.34
▸ IP6K1 Q92551 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ ADRA1B P35368 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507117 1.00 PGR (0.40) PGRALKPTGS2HTR1AHTR2A
SCHEMBL30507086 0.89 ALK (0.42) PGRALKPTGS2KCNA5
SCHEMBL25317063 0.89 PGR (0.41) PGRALKHTR1AHTR2AHTR7
SCHEMBL25317654 0.89 ALK (0.42) PGRALKPTGS2KCNA5
SCHEMBL25317873 0.87 PGR (0.40) PGRALKHTR1AHTR2AHTR7
SCHEMBL26043799 0.87 PGR (0.42) PGRALKKCNA5TRPV4IP6K1
SCHEMBL25317352 0.87 PGR (0.40) PGRALKHTR1AHTR2AHTR7
SCHEMBL25317489 0.87 PGR (0.40) PGRALKHTR1AHTR2AHTR7
SCHEMBL25314599 0.87 HTR7 (0.42) HTR1AHTR2AHTR7HTR6IP6K1
SCHEMBL30506784 0.87 HTR7 (0.42) HTR1AHTR2AHTR7HTR6IP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR PGR 2819/4885ALK 4587/4885PTGS2 3430/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 PGR 2960/4885ALK 4572/4885PTGS2 3437/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR PGR 2819/4885ALK 4587/4885PTGS2 3430/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 PGR 2960/4885ALK 4572/4885PTGS2 3437/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 PGR 2960/4885ALK 4572/4885PTGS2 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.